SCHEMBL14917372

SCHEMBL14917372

Fc1cc2nc(N3CC(F)(F)C3)c(-c3nn[nH]n3)c(-c3ccccc3)c2cc1Cl

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 9/20 0.78
FABP5 Q01469 9/20 0.78
CYP2C9 P11712 4/20 0.58
FABP3 P05413 3/20 0.58
CYP2D6 P10635 3/20 0.58
DHODH Q02127 2/20 0.38
ABCG2 Q9UNQ0 1/20 0.35
CYP3A4 P08684 1/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C19 P33261 1/20 0.34
ESR2 Q92731 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GP6 Q9HCN6 1/20 0.34
CSNK2A1 P68400 2/20 0.34
ACLY P53396 1/20 0.33
IDO1 P14902 1/20 0.33
MDM2 Q00987 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14917281 0.91 FABP4 (0.79) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14916244 0.88 FABP4 (1.00) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14927294 0.83 FABP4 (0.54) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14917236 0.77 FABP4 (0.66) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14917038 0.76 FABP4 (0.68) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14927298 0.75 FABP4 (0.56) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14917029 0.75 FABP4 (1.00) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14917174 0.75 FABP4 (1.00) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL25334225 0.73 FABP4 (1.00) FABP4FABP5CYP2C9FABP3CYP2D6
SCHEMBL14917385 0.72 FABP4 (0.75) FABP4FABP5CYP2C9FABP3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773619-B1 NEW ARYL-QUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-11-16 EP claimed
US-20160060270-A1 New Aryl-Quinoline Derivatives HOFFMANN-LA ROCHE INC. 2016-03-03 US claimed
US-9199938-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2015-12-01 US claimed
EP-2773619-A1 NEW ARYL-QUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-09-10 EP claimed
WO-2013064465-A1 NEW ARYL-QUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-05-10 WO claimed
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US claimed
US-9809599-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2017-11-07 US disclosed
EP-2773619-B1 NEW ARYL-QUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-11-16 EP disclosed
US-20160060270-A1 New Aryl-Quinoline Derivatives HOFFMANN-LA ROCHE INC. 2016-03-03 US disclosed
US-9199938-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2015-12-01 US disclosed
EP-2773619-A1 NEW ARYL-QUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-09-10 EP disclosed
WO-2013064465-A1 NEW ARYL-QUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-05-10 WO disclosed
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES FABP1, FABP4, FABP5 FABP4 2/4885FABP5 3/4885CYP2C9 2108/4885
US-20160060270-A1 New Aryl-Quinoline Derivatives FABP1, FABP4, FABP5 FABP4 2/4885FABP5 3/4885CYP2C9 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.